Clinical Trials Directory

Trials / Terminated

TerminatedNCT00970424

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Pioglitazone

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
252 (actual)
Sponsor
Forest Laboratories · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background treatment with pioglitazone.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboplacebo, oral tablet administered once daily on background of pioglitazone
DRUGDutogliptindutogliptin, oral tablet administered once daily on background of pioglitazone

Timeline

Start date
2009-08-01
Primary completion
2010-08-01
First posted
2009-09-02
Last updated
2011-09-21

Locations

118 sites across 6 countries: United States, Belarus, Germany, India, Lithuania, Romania

Source: ClinicalTrials.gov record NCT00970424. Inclusion in this directory is not an endorsement.

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitaz (NCT00970424) · Clinical Trials Directory